- Record: found
- Abstract: found
- Article: found
Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma
Laurence Albiges ,
Tom Powles ,
Michael Staehler ,
Karim Bensalah ,
Rachel H. Giles ,
Milan Hora ,
Markus A. Kuczyk ,
Thomas B. Lam ,
Börje Ljungberg ,
Lorenzo Marconi ,
Axel S. Merseburger ,
Alessandro Volpe ,
Yasmin Abu-Ghanem ,
Saeed Dabestani ,
Sergio Fernández-Pello ,
Fabian Hofmann ,
Teele Kuusk ,
Rana Tahbaz ,
Axel Bex
August 2019
August 2019
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Recent randomised trials have demonstrated a survival benefit for a front-line ipilimumab
and nivolumab combination therapy, and pembrolizumab and axitinib combination therapy
in metastatic clear-cell renal cell carcinoma. The European Association of Urology
Guidelines Panel has updated its recommendations based on these studies. PATIENT SUMMARY:
Pembrolizumab plus axitinib is a new standard of care for patients diagnosed with
kidney cancer spread outside the kidney and who did not receive any prior treatment
for their cancer (treatment naïve). This applies to all risk groups as determined
by the International Metastatic Renal Cell Carcinoma Database Consortium criteria.